Letter: Killing Fields

While my name is not Don Quixote, I believe I must fight like him to remain active in science at this time in history. We have created "killing fields," in killing each other's manuscripts and grants. In my environment, this happens far too often, and I am sure many readers have had similar experiences. Most probably share my failure to understand why scientists accept this behavior from each other, and why we don't succeed in reforming the system. (See "Foreign-Born Scientists Face Special Cha

Written byBert Ph.M. Menco
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

While my name is not Don Quixote, I believe I must fight like him to remain active in science at this time in history. We have created "killing fields," in killing each other's manuscripts and grants. In my environment, this happens far too often, and I am sure many readers have had similar experiences. Most probably share my failure to understand why scientists accept this behavior from each other, and why we don't succeed in reforming the system. (See "Foreign-Born Scientists Face Special Challenges In The U.S.," The Scientist, June 25, 1990, page 17.)

I offer an example of my own experiences. I submitted what I considered to be a valid, thorough, biologically significant, and well-assembled manuscript to a respectable journal. The work was a one-man effort, and was based on my work in freeze-etching and freeze-substitution. Since English is not my primary language, the article was professionally proofread before ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies